Defining Sarcopenic Obesity in the Asian Working Group for Sarcopenia 2025 Era: Diagnostic Precision Matters ― Reply ―
Abstract
tables, figures, statistical results or conclusions.The same AWGS 2025 thresholds were also applied in our previous study.4 On behalf of all the authors, I deeply apologize for the confusion caused by this error and immediate steps are being taken to formally correct the published text.Finally, regarding the point that the absence of statistical significance does not establish equivalence.The comparison between newly classified and persistent SO was exploratory, and no equivalence or noninferiority analysis was performed or intended.Indeed, the hazard ratio of 0.748 had a wide 95% confidence interval of 0.254-2.204,which does not exclude clinically meaningful differences in either direction.As explicitly stated in the Limitations section, the modest sample size, particularly within the SO reclassification subgroups, limited statistical power.Therefore, our finding should be interpreted only as indicating that no statistically significant difference was detected, rather than demonstrating equivalence between the groups.The correspondents are to be thanked for emphasizing this important distinction.The insightful comments from Drs. Yoshimura and Matsumoto are greatly appreciated, as they help clarify the scope and appropriate interpretation of our findings.
Related
- Defining Sarcopenic Obesity in the Asian Working Group for Sarcopenia 2025 Era: Diagnostic Precision Matters
- Urinary organophosphate flame retardants and risk of sarcopenia and sarcopenic obesity among middle-aged and older adults: a systematic investigation integrating epidemiological and adverse outcome pathway analyses
- Sarcopenia and Sarcopenic Obesity in Postmenopausal Women: Limitations of BMI as a Predictor of Sarcopenic Obesity.
- GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity
- Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure
BibTeX
@article{ozaki2026defining,
title = {{Defining Sarcopenic Obesity in the Asian Working Group for Sarcopenia 2025 Era: Diagnostic Precision Matters ― Reply ―}},
author = {Yuta Ozaki},
journal = {Circulation Journal},
year = {2026},
month = sep,
doi = {10.1253/circj.cj-26-0925},
url = {https://www.jstage.jst.go.jp/article/circj/90/10/90_CJ-26-0925/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Defining Sarcopenic Obesity in the Asian Working Group for Sarcopenia 2025 Era: Diagnostic Precision Matters ― Reply ―
AU - Yuta Ozaki
PY - 2026
DA - 2026/09/25
JO - Circulation Journal
DO - 10.1253/circj.cj-26-0925
UR - https://www.jstage.jst.go.jp/article/circj/90/10/90_CJ-26-0925/_article
AB - tables, figures, statistical results or conclusions.The same AWGS 2025 thresholds were also applied in our previous study.4 On behalf of all the authors, I deeply apologize for the confusion caused by this error and immediate steps are being taken to formally correct the published text.Finally, regarding the point that the absence of statistical significance does not establish equivalence.The comparison between newly classified and persistent SO was exploratory, and no equivalence or noninferiority analysis was performed or intended.Indeed, the hazard ratio of 0.748 had a wide 95% confidence interval of 0.254-2.204,which does not exclude clinically meaningful differences in either direction.As explicitly stated in the Limitations section, the modest sample size, particularly within the SO reclassification subgroups, limited statistical power.Therefore, our finding should be interpreted only as indicating that no statistically significant difference was detected, rather than demonstrating equivalence between the groups.The correspondents are to be thanked for emphasizing this important distinction.The insightful comments from Drs. Yoshimura and Matsumoto are greatly appreciated, as they help clarify the scope and appropriate interpretation of our findings.
SN - 1347-4820
SN - 1346-9843
ER -